NRAS mutations in AML (~10-15%) — adverse prognostic in some contexts; not directly targe...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NRAS-Q61R-AML |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-AML |
| Sources | SRC-CIVIC SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Actionability Facts
| Biomarker | BIO-RAS-MUTATION |
|---|---|
| Variant | NRAS Q61R |
| Disease | DIS-AML |
| ESCAT tier | IIIA |
| Recommended combinations | clinical trial enrollment |
| Evidence summary | NRAS mutations in AML (~10-15%) — adverse prognostic in some contexts; not directly targeted. Trametinib + venetoclax / azacitidine combos in trial. |
Notes
ESCAT IIIA. Under BIO-RAS-MUTATION (no dedicated BIO-NRAS-Q61R yet — flag for BIO authoring).
Used By
No reverse references found in the YAML corpus.